Immix Biopharma, a clinical-stage biotech focused on CAR-T cell treatments for AL amyloidosis, reported in its latest quarter continued progress with its lead candidate NXC-201, showing encouraging interim clinical results including a high complete response rate in its NEXICART-2 trial. The company holds the FDA Breakthrough Therapy Designation for NXC-201 and is preparing for Biologics License Application submission. A recent $150 million equity raise provides runway into late 2026, mitigating immediate funding concerns. However, as with many early-stage cell therapy developers, Immix faces risks related to final trial outcomes, regulatory approval uncertainties, and sustaining operations beyond current capital.